Company intelligence / Profile preview

XYTOS

Palo Alto, California, USA

Ownership: Private
Development stage: Other

Overview

Xytos was a biotechnology company that specialized in 'Advanced Personalized Medicine' (APM) for oncology. The company's primary focus was the development of individualized treatment protocols that combined diagnostic imaging, photodynamic therapy, and immunotherapy to target solid tumors. Their pipeline included programs for breast cancer, glioblastoma, and prostate cancer, often utilizing technologies developed in collaboration with European medical centers. Xytos operated as a publicly traded company on the OTC markets but has since become inactive following financial and regulatory difficulties.

Therapeutic areas: Oncology
Modalities: Cell therapyPhotodynamic therapy
Industry: Biotech

Beyond the preview

Go deeper on XYTOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYTOS.

Explore the full profile